Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD‐L1

Despite their potent antitumor activity, clinical application of immune checkpoint inhibitors has been significantly limited by their poor response rates (<30%) in cancer patients, primarily due to immunosuppressive tumor microenvironments. As a representative immune escape mechanism, cancer‐deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jung Min, Lee, Chan‐Hyeong, Son, Soyoung, Kim, Chan Ho, Lee, Jae Ah, Ko, Hyewon, Shin, Sol, Song, Seok Ho, Park, Seong‐Sik, Bae, Ju‐Hyun, Park, Ju‐Mi, Choe, Eun‐Ji, Baek, Moon‐Chang, Park, Jae Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844465/
https://www.ncbi.nlm.nih.gov/pubmed/34927389
http://dx.doi.org/10.1002/advs.202103245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844465/
https://www.ncbi.nlm.nih.gov/pubmed/34927389
http://dx.doi.org/10.1002/advs.202103245

Ejemplares similares